二甲双胍与小于胎龄儿:妊娠期糖尿病二甲双胍随机安慰剂对照临床试验(EMERGE)的发现
EMERGE试验的预设次要分析纳入活产且已知出生体重和分娩孕周的女性,比较二甲双胍组与安慰剂组小于胎龄儿(SGA)数量并探索基线预测因素。多变量校正后无基线母体变量与SGA相关,子痫前期与SGA强烈相关,二甲双胍暴露的SGA婴儿未显示更严重表型。
要点
- 子痫前期与SGA强烈相关。
- 多变量校正后无基线母体变量与SGA相关。
- 二甲双胍暴露的SGA婴儿未显示更严重SGA表型。
核心结论
- 子痫前期与SGA婴儿强烈相关。
- 二甲双胍暴露的SGA婴儿未显示比安慰剂治疗婴儿更严重的SGA表型。
研究设计与样本
- EMERGE试验的预设次要分析,该试验评估二甲双胍与安慰剂治疗妊娠期糖尿病(GDM)的有效性,发现二甲双胍使用减少孕期体重增加并延长至胰岛素起始时间。
- 纳入活产且已知婴儿出生体重和分娩孕周的女性。
- 比较两组SGA婴儿数量并探索基线预测因素以识别分娩SGA婴儿风险最高者。
主要发现
- SGA与非SGA妊娠的基线母体特征相似。
- 多变量校正回归中,无基线母体变量与SGA状态相关。
- SGA婴儿母亲更可能发生子痫前期或妊娠期高血压(18.2% vs 2.0%,p=0.001;22.7% vs 5.4%,p=0.005)。
- 多变量校正后,子痫前期与SGA状态正相关。
- SGA妊娠中,二甲双胍组与安慰剂组早产、剖宫产和新生儿监护病房入住率无差异(20.0% vs 14.3%,p=1.00;50.0% vs 28.6%,p=0.25;13.3% vs 42.9%,p=0.27)。
关键数值与推荐
- SGA婴儿母亲子痫前期发生率18.2% vs 非SGA 2.0%(p=0.001)。
- SGA婴儿母亲妊娠期高血压发生率22.7% vs 非SGA 5.4%(p=0.005)。
- SGA妊娠中二甲双胍组 vs 安慰剂组早产20.0% vs 14.3%(p=1.00)。
- SGA妊娠中二甲双胍组 vs 安慰剂组剖宫产50.0% vs 28.6%(p=0.25)。
- SGA妊娠中二甲双胍组 vs 安慰剂组新生儿监护病房入住13.3% vs 42.9%(p=0.27)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes because of suboptimal glucose management and glucose control and excessive weight gain. Metformin can offset these factors but is associated with small for gestational age (SGA) infants. We sought to identify risk factors for SGA infants, including the effect of metformin exposure on SGA status. METHODS: In this prespecified secondary analysis of the EMERGE trial, which evaluated the effectiveness of metformin vs placebo in treating GDM and found reduced gestational weight gain and longer time to insulin initiation with metformin use, we included women with a live-born infant and known infant birthweight and gestational age at delivery. We compared the numbers of SGA infants in both groups and explored baseline predictive factors to help identify those at highest risk of delivering an SGA infant. RESULTS: Baseline maternal characteristics were similar between SGA and non-SGA pregnancies. On multivariable-adjusted regression, no baseline maternal variables were associated with SGA status. Mothers of SGA infants were more likely to develop pre-eclampsia or gestational hypertension (18.2% vs 2.0%, p=0.001; 22.7% vs 5.4%, p=0.005, respectively); after multivariable adjustment, pre-eclampsia was positively associated with SGA status). Among SGA pregnancies, important perinatal outcomes including preterm birth, Caesarean delivery and neonatal care unit admission did not differ between the metformin and placebo groups (20.0% vs 14.3%, p=1.00; 50.0% vs 28.6%, p=0.25; 13.3% vs 42.9%, p=0.27, respectively). CONCLUSIONS/INTERPRETATION: Pre-eclampsia was strongly associated with SGA infants. Metformin-exposed SGA infants did not display a more severe SGA phenotype than infants treated with placebo. TRIAL REGISTRATION: Clinical Trials.gov NCT02980276; EudraCT number: 2016-001644-19.
引用
- Dunne F, Newman C, Alvarez-Iglesias A, et al. Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE). Diabetologia. 2024. PMID: 39215812. doi:10.1007/s00125-024-06252-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。